RecruitingPhase 1NCT05869955
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- CC-97540(drug)
- Enrollment
- 270 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Local Institution - 0048, New Haven, Connecticut, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, United States
- Local Institution - 0053, Chicago, Illinois, United States
- Local Institution - 0030, Baltimore, Maryland, United States
- Local Institution - 0038, Boston, Massachusetts, United States
- Local Institution - 0046, Boston, Massachusetts, United States
- University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Henry Ford Medical Center - New Center One, Detroit, Michigan, United States
- Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Local Institution - 0028, Omaha, Nebraska, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb Services Unlimited Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05869955 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University